Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company dedicated to the development and commercialization of novel therapies for the treatment of inflammatory and fibrotic diseases by leveraging its rationally designed, endocannabinoid system-targeted drug candidates. The company's lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist, rationally designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.